Clinuvel Pharmaceuticals Ltd
ASX:CUV
Intrinsic Value
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. [ Read More ]
The intrinsic value of one
CUV
stock under the Base Case scenario is
18.84
AUD.
Compared to the current market price of 14.99 AUD,
Clinuvel Pharmaceuticals Ltd
is
Undervalued by 20%.
Clinuvel Pharmaceuticals Ltd's market capitalization is 751.4m AUD.
CUV stock price is 14.99 AUD.
CUV stock price (14.99 AUD) is 20% less than its Intrinsic Value (18.84 AUD).
CUV stock price (14.99 AUD) is 30% less than its Relative Value (21.51 AUD). Open Relative Valuation
CUV has upside potential of 80% compared to the average analyst price target.
Open Wall St Estimates
CUV's Revenue has grown by an exceptional 21% over the past 12 months.
CUV's ROE (Return on Equity) for the past 12 months is positive and is equal to 19%.
CUV's Revenue is forecast to grow at a rate of 11% per year over the next 3 years.
CUV's ROE (Return on Equity) has decreased in the last 3 years from 28% to 19%.
CUV's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 255% to 145%.
CUV has positive three-year average ROE (Return on Equity): 23%. The company is efficient at transforming stockholders' equity into net income.
CUV's Revenue has been growing by an exceptional 31% per year for the last 3 years.
CUV has positive Operating Income for the last twelve months.
CUV has positive Net Income for the last twelve months.
CUV's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 145%.
CUV has positive Gross Profit for the last twelve months.
CUV has positive Free Cash Flow for the last twelve months.
CUV's D/E (Debt to Equity) is very low and is equal to 0.
CUV has very high three-year average ROIC (Return on Invested Capital): 183%. The company is very efficient at using invested capital to generate operating income.
CUV's short-term assets (201m AUD) exceed its short-term liabilties (29m AUD).
CUV's long-term assets (212m AUD) exceed its long-term liabilties (33m AUD).
CUV has negative Net Debt. This means that the company has more cash and short-term investments (174m AUD) than debt (713k AUD).
CUV's Altman Z-Score is very high and is equal to 15.82.
Valuation Backtest
Clinuvel Pharmaceuticals Ltd
Run backtest to discover the historical profit from buying and selling
CUV
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Clinuvel Pharmaceuticals Ltd
Balance Sheet Decomposition
Clinuvel Pharmaceuticals Ltd
| Current Assets | 201.5m |
| Cash & Short-Term Investments | 174.4m |
| Receivables | 13.1m |
| Other Current Assets | 14m |
| Non-Current Assets | 10.2m |
| PP&E | 7.9m |
| Intangibles | 185k |
| Other Non-Current Assets | 2.1m |
| Current Liabilities | 29.4m |
| Accounts Payable | 6.5m |
| Other Current Liabilities | 22.9m |
| Non-Current Liabilities | 3.6m |
| Long-Term Debt | 713.1k |
| Other Non-Current Liabilities | 2.9m |
Earnings Waterfall
Clinuvel Pharmaceuticals Ltd
|
Revenue
|
87.3m
AUD
|
|
Cost of Revenue
|
8.1m
AUD
|
|
Gross Profit
|
95.4m
AUD
|
|
Operating Expenses
|
-44.5m
AUD
|
|
Operating Income
|
50.8m
AUD
|
|
Other Expenses
|
-20.7m
AUD
|
|
Net Income
|
30.2m
AUD
|
Free Cash Flow Analysis
Clinuvel Pharmaceuticals Ltd
CUV Profitability Score
Profitability Due Diligence
Clinuvel Pharmaceuticals Ltd's profitability score is 79/100. The higher the profitability score, the more profitable the company is.
Score
Clinuvel Pharmaceuticals Ltd's profitability score is 79/100. The higher the profitability score, the more profitable the company is.
CUV Solvency Score
Solvency Due Diligence
Clinuvel Pharmaceuticals Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Clinuvel Pharmaceuticals Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CUV Price Targets Summary
Clinuvel Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
CUV
is 26.94 AUD
with a low forecast of 16.16 AUD and a high forecast of 48.62 AUD.
Shareholder Return
CUV Price
Clinuvel Pharmaceuticals Ltd
| Average Annual Return | 2.32% |
| Standard Deviation of Annual Returns | 29.34% |
| Max Drawdown | -71% |
| Market Capitalization | 751.4m AUD |
| Shares Outstanding | 50 127 300 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Clinuvel Pharmaceuticals Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.
Contact
IPO
Employees
Officers
The intrinsic value of one
CUV
stock under the Base Case scenario is
18.84
AUD.
Compared to the current market price of 14.99 AUD,
Clinuvel Pharmaceuticals Ltd
is
Undervalued by 20%.
You don't have any saved screeners yet
